US Patent Office Reverses Cancellation of Longhorn Vaccines’ Claims, Signaling Policy Shift

In a recent decision that signals a shift in policy, the acting director of the U.S. Patent and Trademark Office has reinstated the patent claims of Longhorn Vaccines & Diagnostics LLC. This comes after the prior director had nullified these claims as a form of sanction for perceived misconduct by Longhorn. The acting director’s stance underscores the belief that the Patent Trial and Appeal Board (PTAB) should refrain from using the cancellation of intellectual property as a punitive measure. This development could influence future PTAB proceedings and set a precedent for how sanctions are applied in patent disputes. Further details on this case can be accessed in the Law360 article.